All In Biotech

Drug Trial Radar · NCT07772492

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Mar 2032

Study completion Mar 2032

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body. Some treatment options are available for adults and adolescents with AA, however there is still high unmet need for systemic treatments (treatment that moves throughout the bloodstream) approved for young patients with AA. Treatments may not work for all patients or may stop working over time. Because of this, researchers are developing new AA treatments, like upadacitinib. Upadacitinib is a type of medicine called a Janus- Kinase (JAK) inhibitor and works with the body to fight the inflammation that can cause AA. In this study, different doses (amounts) of upadacitinib are being compared to treatment with placebo (looks like the study treatment but contains no medicine). Upadacitinib is an investigational JAK inhibitor being developed for the treatment of severe alopecia areata in pediatric patients. This is a randomized, double-blind, placebo-controlled study. Participants are placed in 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. Pediatric participants with a diagnosis of severe alopecia areata with SALT score ≥ 50 scalp hair loss will be enrolled. Participants will be at least 6 years old at Screening and less than 18 years old at Baseline. Approximately 300 participants will be enrolled in the study at approximately 120 sites worldwide. Participants will receive oral doses of upadacitinib or matching placebo daily, or twice daily, for approximately 160 weeks. The study comprises a 35-day Screening Period, a 24-week placebo-controlled double-blinded treatment period (Period A), a 28-week blinded extension treatment period (Period B), a 108-week blinded long-term extension period (Period C), and a 30-day follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Severe Alopecia Areata

Interventions

  • UpadacitinibDrug

    Oral

  • PlaceboDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss.Time frame: At Week 24
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Week 160

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • Dermatology Research Associates - Los Angeles /ID# 282821

    Los Angeles, California · Recruiting

  • Pediatric Skin Research - Miami /ID# 283281

    Miami, Florida · Recruiting

  • Ada West Research /ID# 283063

    Meridian, Idaho · Recruiting

  • Dawes Fretzin- Indianapolis /ID# 283498

    Indianapolis, Indiana · Recruiting

  • Washington University School of Medicine - St. Louis /ID# 282819

    St Louis, Missouri · Recruiting

  • Skin Specialists /ID# 283358

    Omaha, Nebraska · Recruiting

  • Red River Research Partners - Fargo /ID# 283517

    Fargo, North Dakota · Recruiting

  • Dermatologists of Southwestern Ohio (DSWO) /ID# 282818

    Fairborn, Ohio · Recruiting

  • 3A Research - East location /ID# 283404

    El Paso, Texas · Recruiting

  • Texas Dermatology and Laser Specialists /ID# 282813

    San Antonio, Texas · Recruiting

  • Virginia Clinical Research /ID# 283797

    Norfolk, Virginia · Recruiting

  • Fundacion Respirar /ID# 283582

    Buenos Aires, Argentina · Recruiting

  • Premier Dermatology - Kogarah /ID# 283484

    Kogarah, New South Wales, Australia · Recruiting

  • Cornerstone Dermatology - Coorparoo /ID# 284160

    Coorparoo, Queensland, Australia · Recruiting

  • Sinclair Dermatology - Melbourne /ID# 283854

    East Melbourne, Victoria, Australia · Recruiting

  • Nagomi Dermatology Clinic /ID# 282713

    Ebina-shi, Kanagawa, Japan · Recruiting

  • Shinsaibashi Inui Dermatology Clinic. /ID# 282706

    Osaka, Osaka, Japan · Recruiting

  • Kyorin University Hospital /ID# 282702

    Mitaka-shi, Tokyo, Japan · Recruiting

  • Clinical Trials New Zealand /ID# 283489

    Hamilton, Waikato Region, New Zealand · Recruiting

  • Chungang University Hospital /ID# 282799

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • National Taiwan University Hospital /ID# 282895

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital /ID# 282900

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.